BCL2 and acute myeloid leukemia: Chyla et al. have reported the results on the clinical outcomes of a group of older AML patients (median age 74 years) undergoing treatment with venetoclax + hypomethylating agents or low-intensity chemotherapy, correlating clinical responses with molecular markers and with the levels of BCL-2 expression [168].